Clinical Trial Update: Oral OKT3 for the Treatment of Active Ulcerative Colitis [Phase 1, Phase 2]

View source ↗

Summary

Results from a Phase 1/2 clinical trial evaluating oral muromonab-CD3 (OKT3) for active ulcerative colitis; the study has completed and results are posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Orthoclone OKT3 (muromonab-CD3)

Snippet

Sponsor: Brigham and Women's Hospital | Conditions: Ulcerative Colitis | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2017-06-14